Chi Sheng Pharma & Biotech Co., Ltd

TPEX:4111 Stock Report

Market Cap: NT$1.6b

Chi Sheng Pharma & Biotech Past Earnings Performance

Past criteria checks 2/6

Chi Sheng Pharma & Biotech has been growing earnings at an average annual rate of 10.1%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 2.3% per year. Chi Sheng Pharma & Biotech's return on equity is 5.8%, and it has net margins of 6.5%.

Key information

10.1%

Earnings growth rate

10.1%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate2.3%
Return on equity5.8%
Net Margin6.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01
Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10
Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Revenue & Expenses Breakdown

How Chi Sheng Pharma & Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:4111 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,1047126719
30 Jun 241,0827326620
31 Mar 241,0657326221
31 Dec 231,0616926022
30 Sep 231,09011626523
30 Jun 231,11515126222
31 Mar 231,13016425420
31 Dec 221,14317924920
30 Sep 221,10518622718
30 Jun 221,08515021919
31 Mar 221,05912921919
31 Dec 211,02210821919
30 Sep 211,0035623319
30 Jun 219714123519
31 Mar 219534623119
31 Dec 209795922918
30 Sep 201,0057222819
30 Jun 201,0268022719
31 Mar 201,0478523420
31 Dec 191,0237223221
30 Sep 199985723322
30 Jun 199855723322
31 Mar 199644622922
31 Dec 189674222923
30 Sep 189855222724
30 Jun 181,0166022724
31 Mar 181,0326922223
31 Dec 171,0458221923
30 Sep 171,0349121320
30 Jun 171,0128820919
31 Mar 179958520919
31 Dec 169647320719
30 Sep 169464821025
30 Jun 169364620726
31 Mar 169384220325
31 Dec 159323920326
30 Sep 159084019120
30 Jun 159225018718
31 Mar 159255918419
31 Dec 149437317818
30 Sep 1497910417718
30 Jun 1497410517617
31 Mar 1496010617316
31 Dec 139219617116

Quality Earnings: 4111 has high quality earnings.

Growing Profit Margin: 4111's current net profit margins (6.5%) are lower than last year (10.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4111's earnings have grown by 10.1% per year over the past 5 years.

Accelerating Growth: 4111's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4111 had negative earnings growth (-38.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.9%).

Return on Equity

High ROE: 4111's Return on Equity (5.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:10
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chi Sheng Pharma & Biotech Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.
Xiaowei HuangMasterlink Securities Corp.